Research and Development Expense, Maximum Aggregate Milestone Payments

No definition available.

Name:	rprx_ResearchAndDevelopmentExpenseMaximumAggregateMilestonePayments
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research And Development Expense, Maximum Aggregate Milestone Payments, Number Of Quarters

+ References

No definition available.

+ Details

Name:	rprx_ResearchAndDevelopmentExpenseMaximumAggregateMilestonePaymentsNumberOfQuarters
Namespace Prefix:	rprx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Upfront Payment

+ References

No definition available.

+ Details

Name:	rprx_ResearchAndDevelopmentExpenseUpfrontPayment
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research And Development, Remaining Funding Commitment

+ References

No definition available.

+ Details

Name:	rprx_ResearchAndDevelopmentRemainingFundingCommitment
Namespace Prefix:	rprx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=rprx_LitifilimabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=rprx_ResearchDevelopmentFundingArrangementWithBiogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rprx_DaraxonrasibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rprx_BiogenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=rprx_CytokineticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Research and Development Funding Expense (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2025 USD ($) quarter
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development funding expense	$ 452,000	$ 2,000	$ 52,000
Litifilimab \| R&D Funding Arrangement With Biogen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unfunded R&D commitment	50,000
Daraxonrasib
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development funding expense	$ 250,000
Biogen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate payments				$ 250,000
Number of quarters \| quarter				6
Biogen \| Litifilimab
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment				$ 50,000
Cytokinetics
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development funding expense			$ 50,000